ZOL with a low dose of IL-2 induced a transient γδ-T cell activation in patients with for example lung cancer or renal cell carcinoma, but this had no clinical effect on tumors [27]. This evidence concerns the gene IL2 and hereditary clear cell renal cell carcinoma.